InvestorsHub Logo
icon url

BTH

05/22/12 11:34 PM

#142402 RE: jq1234 #142401

Is the P3 metmab trial one with a diagnostic for high-low met pts?

The P3 Arq trial is non-squ NSCLC but without a diagnostic?

Either way, I think the MARQUEE study will be a success....but, generally, when a stock declines from 8.50 to 5.40 with a constant drip of 3% daily, and 18 out of 20 days "red", I am missing something, or someone leaked something.
icon url

Summer2762

05/23/12 1:23 PM

#142426 RE: jq1234 #142401

I think investors expected a little bit better HCC data. At least I did. That might be the reason of the latest weakness.